Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 62, Issue 4, Pages 1519-1525Publisher
IOS PRESS
DOI: 10.3233/JAD-170993
Keywords
A beta(1-42); cerebrospinal fluid; frontotemporal lobar degeneration; LDL-cholesterol; P-tau; PCSK9; T-tau
Categories
Funding
- Fondation LEDUCQ [13CVD03]
- Fundazione CARIPLO
Ask authors/readers for more resources
The role of PCSK9 in Alzheimer's disease (AD) is controversial. We compared cerebrospinal fluid (CSF) PCSK9 concentrations in 36 AD and 31 non-AD patients. CSF PCSK9 levels did not differ between AD and non-AD groups (2.80 versus 2.62 ng/mL). However, PCSK9 CSF levels were increased in AD and non-AD patients with other neurodegenerative process (non-AD ND, n = 20) compared to patients without neurodegenerative disorders (non-ND, n = 11): 2.80 versus 2.30 (p < 0.005) and 2.83 versus 2.30 ng/mL (p = NS), respectively. CSF PCSK9 were positively correlated with AD biomarkers (A beta(1-42), T-tau, and P-tau). PCSK9 concentrations in CSF are increased in neurodegenerative disorders rather than specifically in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available